|
STK40 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.76749997865744E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.77999999873802E-08 |
| Normal-vs-Stage2 |
6.573500E-02 |
| Normal-vs-Stage3 |
3.05749869866645E-11 |
| Normal-vs-Stage4 |
2.07960000331298E-08 |
| Stage1-vs-Stage2 |
1.146160E-02 |
| Stage1-vs-Stage3 |
1.747870E-02 |
| Stage1-vs-Stage4 |
4.704100E-02 |
| Stage2-vs-Stage3 |
5.609400E-04 |
| Stage2-vs-Stage4 |
8.042300E-04 |
| Stage3-vs-Stage4 |
6.977800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.74400502320304E-11 |
| Normal-vs-AfricanAmerican |
4.199000E-03 |
| Normal-vs-Asian |
2.44329999998794E-06 |
| Caucasian-vs-AfricanAmerican |
2.772200E-01 |
| Caucasian-vs-Asian |
7.334600E-01 |
| AfricanAmerican-vs-Asian |
4.682000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.31219999813348E-08 |
| Normal-vs-Female |
2.4342999949134E-08 |
| Male-vs-Female |
3.387400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.38600000032518E-07 |
| Normal-vs-Age(41-60Yrs) |
1.00570000105549E-08 |
| Normal-vs-Age(61-80Yrs) |
1.42560000004899E-06 |
| Normal-vs-Age(81-100Yrs) |
6.142200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.607400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.703200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.350600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.247600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.737400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.821600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.7774995071137E-10 |
| Classical-VS-Follicular |
2.40329999999789E-05 |
| Classical-VS-Other |
2.556000E-01 |
| Classical-VS-Normal |
9.65938440344871E-12 |
| Tall-VS-Follicular |
4.60187443707127E-13 |
| Tall-VS-Other |
4.478600E-01 |
| Tall-VS-Normal |
8.88178419700125E-16 |
| Follicular-VS-Other |
3.648500E-02 |
| Follicular-VS-Normal |
1.271050E-01 |
| Other-VS-Normal |
7.595600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.70830000000488E-05 |
| Normal-vs-N1 |
9.19200271454201E-11 |
| N0-vs-N1 |
6.0390999999993E-05 |
|
|
